Burkitt lymphoma (BL) is the most common histological subtype of nonHodgkin lymphoma (NHL) in children and adolescents. Through the introduction of short intensive multi-agent chemoimmunotherapy, survival has improved significantly over the past 30 years. However, this successful approach is limited by significant chemotherapy-induced acute toxicity and risk of developing resistant disease, demonstrating the need to identify less toxic and targeted therapies. We analysed the comparative genomic signature and targetable signalling pathways in paediatric BL (PEBL) samples from the Children's Oncology Group study (ANHL01P1) by genomic profiling and selected genes were confirmed by quantitative real time polymerase chain reaction. These results were compared to PEBL samples from public databases and utilised the Gene Expression Omnibus (GEO) Series (GSE) 10172 and 4475 (n = 16), and 4732 (n = 15). Three hundred and seventy-six genes (approximately 25%) were similarly expressed among three PEBL sample groups. Several target genes in Toll-like receptor signalling, JAK-STAT signalling and MAPK signalling were significantly overexpressed in PEBL. In addition, several tyrosine kinases, including Bruton tyrosine kinase, protein tyrosine phosphatase and histone deacetylase inhibitor were highly expressed in PEBL. These pre-clinical results suggest that specific signal transduction pathways are overly expressed in PEBL and several pathways could serve as potential future therapeutic targets.
Summary
Burkitt lymphoma (BL) is the most common histological subtype of nonHodgkin lymphoma (NHL) in children and adolescents. Through the introduction of short intensive multi-agent chemoimmunotherapy, survival has improved significantly over the past 30 years. However, this successful approach is limited by significant chemotherapy-induced acute toxicity and risk of developing resistant disease, demonstrating the need to identify less toxic and targeted therapies. We analysed the comparative genomic signature and targetable signalling pathways in paediatric BL (PEBL) samples from the Children's Oncology Group study (ANHL01P1) by genomic profiling and selected genes were confirmed by quantitative real time polymerase chain reaction. These results were compared to PEBL samples from public databases and utilised the Gene Expression Omnibus (GEO) Series (GSE) 10172 and 4475 (n = 16), and 4732 (n = 15). Three hundred and seventy-six genes (approximately 25%) were similarly expressed among three PEBL sample groups. Several target genes in Toll-like receptor signalling, JAK-STAT signalling and MAPK signalling were significantly overexpressed in PEBL. In addition, several tyrosine kinases, including Bruton tyrosine kinase, protein tyrosine phosphatase and histone deacetylase inhibitor were highly expressed in PEBL. These pre-clinical results suggest that specific signal transduction pathways are overly expressed in PEBL and several pathways could serve as potential future therapeutic targets.
Keywords: gene expression profiles, paediatric Burkitt lymphoma, signal transduction pathways.
(COG), together with the United Kingdom Children's Cancer Group (UKCCSG) and the French Paediatric Oncology Group (SFOP), conducted a prospective international study in PEBL [French-American-British (FAB) 96] that demonstrated 90% 5-year overall survival (OS) including patients with stage III/IV disease and those with bone marrow (BM) and central nervous system (CNS) disease Patte et al, 2007; Gerrard et al, 2008) . More recently, we have demonstrated the safety and efficacy of adding rituximab to the chemotherapy backbone (FAB 96) in children and adolescents with advanced mature Burkitt lymphoma (BL) (COG ANHL01P1) (Goldman et al, , 2014 . However, this success has come at the cost of the significant chemotherapy-induced acute toxicity secondary to intensive chemotherapy, requiring the need to identify less toxic but targeted therapy. Furthermore, patients with PEBL who relapse or progress have chemotherapy-resistant disease and can rarely be salvaged Miles et al, 2012) . These results suggest the urgent need to identify alternative treatment approaches focusing on targeted therapy to circumvent chemotherapy-resistant disease by providing alternative therapeutic targets.
The rearrangement of proto-oncogene MYC on 8q24 is the hallmark cytogenetic feature of BL (Dave et al, 2006; Poirel et al, 2009; Nelson et al, 2010) . The activation of MYC has been implicated in the promotion of aberrant cell proliferation (Shaffer et al, 2002) . A set of MYC target genes were identified in both paediatric and adult BL samples by comparing all subtypes of diffuse large B-cell lymphoma (DLBCL) with samples of BL (Dave et al, 2006; Hummel et al, 2006; Klapper et al, 2008; Deffenbacher et al, 2012; Giulino-Roth et al, 2012) . These results suggested that BL, in part, uses different oncogenic signalling pathway(s) compared to other B-cell lymphomas, including DLBCL. Unlike many other haematological malignancies, the nuclear factor (NF)-kB pathway was not constitutively activated in BL (Dave et al, 2006) and recently, the phosphatidylinositol 3-kinase (PI3K) pathway has been suggested as a key signalling pathway in BL lymphomagenesis (Sander et al, 2012) . However, it is still unclear whether diverse signalling pathway(s) contribute to paediatric Burkitt lymphomagenesis. While it is important to know the degree of variability in the pathogenetic networks, a fuller understanding of these, as well as the key points in the pathways, could lead to more rational target selection than simply identifying the pathway of genes in the molecular signature. In this study we analysed the comparative genomic signatures of PEBL among COG PEBL samples from the most recent COG PEBL Study (COG ANHL01P1) and compared our results with the databases of Berlin-Frankfurt-Muenster (BFM) NHL samples (Klapper et al, 2008) and National Cancer Institute (NCI) samples (Dave et al, 2006) . This approach demonstrated several potential targetable signalling pathways in PEBL.
Materials and methods

Patient samples
Primary tumour specimens were obtained from children and adolescents with newly diagnosed stage III/IV or BM AE CNS BL registered on the COG ANHL01P1 study (Clinicaltrials.-gov NCT00057811) (Goldman et al, , 2014 that were submitted to the reference laboratory at Columbia University. The protocol was approved by the institutional review board of each COG centre participating in this trial. Samples (1-2 ml) of PEBL patient-involved BM, pleural fluid, peritoneal fluid and/or lymph node with tumour involvement were collected at the time of diagnosis. The specimens for molecular studies were immediately submerged in RNAlater reagent (Qiagen, Valencia, CA, USA), and shipped overnight at room temperature to the central research laboratory at Columbia University. Upon receipt, the specimens in RNA later were immediately processed to extract total RNA and frozen at À80°C.
Haematopathology
All cases underwent central pathology review for confirmation of diagnosis, consisting of review of morphology, immunophenotype and genetic data from the original diagnostic biopsy. If required, additional immunophenotyping was performed centrally to confirm the diagnosis according to the 2008 World Health Organization Classification (Swerdlow et al, 2008) . In addition, CD20 expression of the tumour was confirmed by immunohistochemistry (L-26 clone; DAKO Cytomation, Carpinteria, CA, USA) using standard methods and heat-induced epitope retrieval in citrate buffer (pH6Á0) on an automated stainer (ES; Ventana Medical Systems, Tucson, AZ, USA). A tumour was scored as CD20 positive if >80% of the tumour cells stained with the antibody.
Cytogenetics and fluorescence in situ hybridization analysis
Cytogenetic analysis was performed, as previously described, with nomenclature according to the International System for Human Chromosome Nomenclature (Shaffer & Tommerup, 2005; Poirel et al, 2009) . Interphase fluorescence in situ hybridization (FISH) analysis for MYC rearrangement was performed on a portion of the specimen submitted for cytogenetic analysis. A dual-colour MYC/IGH translocation probe designed to detect t(8;14)(q24.1;q32) or a dual-colour MYC break-apart probe, designed to detect rearrangements of the MYC gene region at 8q24.1 with various partner chromosomes, was utilised according to the COG reference laboratories standard protocols. Slides were counterstained with 4,6-diamidino-2-phenylindole (DAPI) in Antifade solution and the nuclei were visualized and captured using a fluorescence microscope equipped with appropriate filters and imaging software.
Clinical characteristics
Specimens were collected from 11 PEBL patients registered on the COG ANHL01P1 study and the clinical and demographic data on these patients are described in Table I . All patients were treated with chemoimmunotherapy with modified FAB B4 and C1 chemotherapy with the addition of rituximab in induction and consolidation as previously described (Shiramizu et al, 2011; Barth et al, 2013; Galardy et al, 2013; Goldman et al, 2013 Goldman et al, , 2014 .
Oligonucleotide cDNA microarray analysis RNA purification and hybridization for the microarray analyses were performed as previously described (Jiang et al, 2009) . In brief, total RNA from patient tumour specimens was isolated by Trizol reagents (Invitrogen, Carlsbad, CA, USA) and followed by affinity column purification (Qiagen). cDNA was generated from 100 ng total RNA using a poly dT oligonucleotide (Affymetrix, Santa Clara, CA, USA). Biotinylated labelling of cRNA was performed by in vitro transcription according to manufacturer's protocol. Fragmented cRNA (15 lg) was hybridized to HG_U133 A2 Gene Chip â arrays (Affymetrix) using Fluidics Station 450 (Affymetrix).
Gene expression profiling
Signal intensities of gene expression were calculated by Expression Console (Affymetrix). Data were imported into GeneSpring GX 10 (Agilent Technologies, Foster City, CA, USA) or Partek Genomics Suite (St. Louis, MI, USA) and normalised and presented as log 2 values. Fold changes of target expression were compared to the average of 530 median expressed genes. The identified gene information and accession numbers were first obtained through NetAffx, provided by Affymetrix, and then each entity was further confirmed by a search of GenBank. Data has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (https://www.ncb i.nlm.nih.gov/geo/; accession number GSE64905).
Quantitative real time polymerase chain reaction
Selected genes (PIM1, STAT1, MAP2K1, RAF1, PTPN11, DLEU1, and MYC), based on being a BL classifier gene or representing different signalling transduction pathways, were examined for their expression levels by quantitative real time polymerase chain reaction (qRT-PCR) using qScript ™ cDNA Synthesis Kit (Quantas, Gaithersburg, MD, USA) and SsoFast ™ EvaGreen â Supermix (Bio-rad, Hercules, CA, USA). The primer sequences are listed in Table SI . Real time detection of the RT-PCR product was monitored using the CFX96 Real-time system (Bio-rad). Relative quantification (ddCt) of mRNA expression of each gene was determined by normalizing to the housekeeping gene GAPDH. cDNA amplification efficiencies of target and reference genes were confirmed to be equivalent and the absolute values of the slope of log input amount versus DC T were <0Á1. Fold changes were obtained by being normalised to the qRT-PCR results of GAPDH expression.
Comparative genomic signature
For the genomic comparison in this study, paediatric genome expression results from three different research groups were utilised (Table SII) ; COG ANHL01P1 in the current study (n = 11), GEO GSE10172 and GSE4475 (Klapper et al, 2008) (n = 16), and GSE4732 (Dave et al, 2006) (n = 15) (≤13 years of age). 
Pathway and function analysis
Functional interpretation of the classified genes with similar expression from the comparative genomic data of COG, NCI and BFM, and relevance to molecular and cellular functions and pathways was generated by Ingenuity Pathways Analysis (IPA â ), version 6.5 (Qiagen, Redwood City, CA, USA). Pvalues less than 0Á05 indicate a statistically significant and non-random association between a set of computational selected genes from the 376 PBL genes and a set of all genes related to a given function in Ingenuity's knowledge base.
Gene functional classification
The genes using Affymetrix ID as the identifier were uploaded into the Database for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) at the National Institute of Health, and then analysed by functional annotation clustering. Gene lists obtained from each functional group were then re-uploaded into DAVID, and then searched for specific pathways.
Statistical analysis
Statistical differences between the three genomic expression profiles were analysed by Student t test; differences between multiple groups were analysed by one-way ANOVA followed by the Tukey multiple comparison test. Results are expressed as mean AE standard error of the mean with probability values less than or equal to 0Á05 considered significant.
Results
Demographics
The mean age of the COG BL patients was 11Á3 years, with a male/female ratio of 9:2. There were 3 stage III and 8 stage IV patients. Seven patients had BM involvement (≥25% L3 blasts) and one patient had CNS disease. Four patients were treated on the group B arm and seven patients were treated on the group C arm (Table I) (Goldman et al, , 2014 .
Haematopathology
All of the cases used in this study showed typical morphological and immunophenotypic features of BL, including CD20, CD10 and BCL6 positivity and lack of expression of T-cell markers and BCL2 protein. In all cases, the tumours showed a high proliferative rate (>95%) by Ki-67 immunohistochemistry.
Cytogenetics
Six of 11 patients had evaluable cytogenetics. One patient was FISH positive for IGH/MYC but had a failed karyotype.
Three patients had a complex karyotype, defined as the presence of 3 or more chromosomal aberrations, and three patients had a t(8;14)(q24;q32) translocation (Table SIII) .
Comparative genomic signature
A total of 1565 genes were identified (P < 0Á05), among which 376 genes showed a similar genomic expression pattern within the PEBL signature among the three clinical subgroups (Fig 1) . MYC, a molecular identifier for BL, showed 27-fold greater expression in these subgroups, consistent with the previous BL signature described by Dave et al (2006) . We further classified these 376 genes and identified 12 major functions (333 genes with known functions and 43 genes with unknown functions) that were involved in PEBL (Fig 2A and B) . Detailed classifications and descriptions of genes in each 12 functional group are listed in Table SIV . The lead functional categories were serine/threonine kinases and tyrosine kinases (87 genes), cytokine binding receptors (80 genes) and transcription (77 genes) (Fig 2A and B) . PEBL tumour samples also demonstrated significantly higher levels of expression of genes, including the protein tyrosine phosphatases (PTP), PTPN11 (also called SHP2; 36Á6-fold), and PTPN6 (8Á6-fold) SHP1). Small GTPases and regulators were also significantly expressed in PEBL (10 genes), including RALBP1 (8Á9-fold), RHOG (9Á7-fold), ARHGAP19 (9Á7-fold), ARHGEF18 (21Á5-fold) and ARHGAP17 (8Á9-fold). Seven glycolysis genes were also significantly overexpressed (8Á1-to 109Á5-fold).
Comparison of genomic profiling and qRT-PCR
To validate the level of gene expression generated from oligonucleotide microarray studies, we analysed a selected number of target genes with significant clinical implication and/or biological function by qRT-PCR. The qRT-PCR results were then compared to the results of microarray analysis. These genes were PIM1, STAT1, MAP2K1, RAF1, PTPN11, DLEU1 and MYC, and the fold changes by qRT-PCR were 4Á7, 10Á3, 8Á7, 21Á3, 35Á0, 8Á1 and 17Á2, respectively (Fig 3) . These qRT-PCR results were consistent with gene expression studies generated from the microarray studies.
Targetable signalling pathways
Within the 376 genes identified as common in all three data sets, IPA â -demonstrated a significant association with three signalling pathways -Toll-like receptor (TOLL) signalling (P < 0Á01), Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signalling (P < 0Á01), and mitogen-activated protein kinase (MAPK) signalling (P < 0Á01) pathways were significantly overexpressed (Fig 4 and Table SV ). We identified gene overexpression of 7 kinases involved in the TOLL pathway and 13 kinases involved in the MAPK pathway from 87 serine/threonine kinases and tyrosine kinases (Table SVI) , and 6 receptor genes involved in the TOLL pathway, JAK-STAT pathway and cytokine binding receptors pathway. Expression of genes involved in the TOLL signalling (Table SVII) included TLR7 (2Á9-fold), IRAK1 (34Á1-fold), NFKBIA (18Á1-fold) and IKBKB (7Á2-fold). In addition, the genes encoding interleukin (IL)-10 receptor (IL10RA; 3Á1-fold) and IL-21 receptor (IL21R; 2Á3-fold) were both expressed at a similar level to TLR7. Expression of genes involved in JAK-STAT signalling (Table SVII) included PIM1 (8Á7-fold), STAT1 (11Á1-fold), TYK2 (4Á1-fold) and IFNAR2 (6Á2-fold) and expression of genes involved in the MAPK signalling in PEBL included MAP2K1 
and PTPN6 (8Á6-fold). Most interestingly, the B cell receptor signalling (BCR) pathway had a significant overexpression of BTK (9Á1-fold) and a significant increase in HDAC1 (42-fold) and HDAC2 (15Á5-fold) (Table SV) .
Discussion
This is the first report using comparative genomic identification to compare the genomic expression signature in PEBL. We compared our COG PEBL samples with PEBL samples reported by the NCI (Dave et al, 2006) and the BFM (Klapper et al, 2008) . These data suggested that PEBL gene expression signatures are consistent among three cooperative groups/laboratories. The fold changes in PEBL gene expression profiles in these three sets of samples were highly similar, if not identical. In addition, the comparative data was remarkable given that these three groups used different designated genechips for microarray. The samples investigated by Dave et al (2006) were processed by custom-made cDNA Lymphochips, while Klapper et al (2008) and our group both utilised Affymetrix Oligonucleotide Genechips (Jiang et al, 2009 ). Our results indicated that TOLL, MAPK, and JAK-STAT signalling pathways are overexpressed in PEBL samples, including threonine kinases, tyrosine kinases and cytokine binding receptors that regulate cellular proliferation (Table SVI) . Interestingly, seven genes involving the regulation of glycolysis (Vander Heiden et al, 2009) were significantly overexpressed in PEBL (Fig 3) , and several target genes involved in the TLR signalling pathway (Table SVI) , TLR7 (2Á9-fold), IRAK1 (34Á1-fold), NFKBIA (18Á1-fold) and IKBKB (7Á2-fold), were significantly overexpressed. In addition, IL10RA (3Á1-fold) and IL21R (2Á3-fold) were both expressed at a similar level to TLR7. The TLRs and the IL1 receptor (IL1R) are known to possess a highly conserved intracellular Toll-IL-1R (TIR) domain (Barton & Medzhitov, 2003) . Furthermore, TLR triggering has been shown to regulate cellular growth in BL (Noack et al, 2012) and TLR activation has been implicated in tonic BCR activation in DLBCL (Akhter et al, 2015) . Ligand activated TLRs cause dimerization of the cytoplasmic TIR domains, which significantly activate the IL-1R associated kinase 1 (i.e. IRAK1) and then further activates the downstream NF-jB signalling. The consequence of this TLR pathway is to enhance the production of interferons (IFNa and IFNb) in PEBL. MAPK has been demonstrated to be overexpressed in EBV-positive versus EBV-negative BL (Cerimele et al, 2005) .
Target genes involved in JAK-STAT signaling (Table SVI) included PIM1 (8Á7-fold), STAT1 (11Á1-fold), TYK2 (4Á1-fold) and IFNAR2 (6Á2-fold), which were also significantly overexpressed. The oncogenic PIM1 has been implicated as a critically important gene with MYC in the pathogenesis of a number of haematological malignancies (Wang et al, 2010) . Furthermore, these preclinical data suggest that the interferons may activate IFNAR2 in PEBL and, in turn, IFNAR2 activates TYK2. The activated TYK2 then phosphorylates STAT1 and STAT4 and may result in dimerization of these transcription factors. The STAT1 and STAT4 dimers may then translocate into the nucleus where they bind on the promoter region of PIM1. This pathway may be partly responsible for PEBL lymphomagenesis. Many MAP kinase signalling pathway genes were significantly overexpressed; target genes involved in MAPK signalling in PEBL (Table SVII) included MAP2K1 (11Á1-fold), MAP3K7 (7Á6-fold), MAPK9 (10Á5-fold), MAP4K4 (8Á3-fold), RAF1 (11Á3-fold), PTPN11 (36Á6-fold) and PTPN6 (8Á6-fold). MAPKs are serine-threonine kinases that regulate a wide variety of cellular functions (Johnson & Lapadat, 2002) . RAF1 encodes a MAP kinase kinase kinase (MAP3K). Mitogen-activated protein kinase (MAPK9), also known as a c-Jun N-terminal kinase (JNK2), blocks the ubiquitination of tumour suppressor TP53 (Johnson & Lapadat, 2002) . PTPN11 and PTPN6 are protein tyrosine phosphatases (Alonso et al, 2004; Ostman et al, 2006) . From these studies we hypothesise that PEBL cells express IFNa or IFNb following induction of TOLL signalling pathways and the overexpression of IRAK1 results in an increase of the TOLL signalling pathway. In addition, an increase of MAP3K7 may enhance the phosphorylation of IKK. These augment phosphorylation of IjBa and IjBb and release of NFjB, then dimerized NFjB bind to the IFNa and IFNb promoters in the nucleus and promote IFNa and IFNb production. These interferons then activate the JAK-STAT and MAPK signalling pathways. Although the functions of these interferons are to enhance apoptosis and reduce proliferation, a highly (Roux & Blenis, 2004) . The interferon-activated IFNAR2-mediated MAPK signalling pathway in PEBL, via RAS proteins, phosphorylates MYC and enhances cellular proliferation and promote anti-apoptosis. Furthermore, serine/threonine kinases and tyrosine kinases were significantly overexpressed in this PEBL genomic study. From these comparative genomic signatures, we have demonstrated that IRAK1, RAF1, MAP4K4, BTK, MAP3K7, MAP2K1, MAPK9, NFKBIA, IKBKB, PIM1, STAT1, PTPN6, and PTPN11 may be candidate targets in the treatment of PEBL. Currently, there are several clinical trials using inhibitors/siRNA of targets in BL in phase I studies, including BTK by ibrutinib (NCT0119069), RAF1 inhibition by regorafenib (NCT02693535) and MYC inhibition by siRNA DCR-MYC (NCT02110563). Additionally, we recently demonstrated that proteins with cellular functions including NF-kB and MAPK signalling pathways are significantly overexpressed in different epidemiological subtypes of BL cell lines compared to normal B cells from healthy donors by proteomic expression profile studies (ElMallawany et al, 2014) .
More interestingly, we have observed a significant increase of BCR signalling pathway genes, including BTK, and have recently demonstrated that the inhibition of PI3K/Akt is a key in a Burkitt lymphomagenesis (Frys et al, 2014) (Ippolito et al, 2015) . BTK is a regulator of normal B-cell development and is activated upon BCR stimulation. Mutations of TCF3 and it's negative regulator ID3, including MYC, are prevalent in BL and contribute to activation of the BCR pathway (Schmitz et al, 2012) (Love et al, 2012) and interestingly, MYC transcriptional expression suppressed small molecule inhibitors of the BET family of chromatin adaptors (Mertz et al, 2011) . However, BL tumourigenesis may be secondary to dysregulation of un-mutated genes via transcription factors versus mutations in the targets of transcription factors or alteration of the function of other genes on the signalling pathway.
Chronic active BCR signalling through BTK activation can be inhibited by the selective, covalent BTK inhibitor, ibrutinib (Davis et al, 2010; Young & Staudt, 2013) . Ibrutinib is an active agent in activated B cell like DLBCL (Mathews Griner et al, 2014) , and preclinical studies in chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) suggested an inhibitory effect on cell proliferation (Honigberg et al, 2010; Ponader et al, 2012; Cinar et al, 2013; Dasmahapatra et al, 2013) . Furthermore, we have recently demonstrated that ibrutinib has a significant inhibitory effect of on cell proliferation and increase in caspase 3/7 and apoptosis in BL (Lee et al, 2015) . Clinically, ibrutinib has been highly effective in the treatment of refractory patients with CLL and MCL and has been approved by the Food and Drug Administration for patients with CLL or MCL who have received at least one prior therapy (Wang et al, 2010 (Wang et al, , 2013 Byrd et al, 2013) .
In summary, this is the first study comparing the genomic signature of PEBL from three completely independent databases. Among the 1565 genes identified, 376 genes (approximately 25%) were similarly expressed between the 3 groups. Furthermore, there was significant overexpression of genes involved in the Toll receptor, JAK-STAT and MAPK signalling pathways. Among these pathways, several genes, including IRAK1, PTPN6, BTK, RAF1, HDAC1 and HDAC2 may be attractive targets for alternate targeted therapeutic strategies in PEBL. methods and results. Dr. Sanger, a dedicated physician-scientist, passed away during the final preparation of this manuscript. Additionally, we would like to acknowledge Erin Morris, RN and Virginia Moore, RN, for their assistance in the preparation of this manuscript. 
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